Cretostimogene grenadenorepvec (CG0070) clinical studies

Our lead candidate, cretostimogene grenadenorepvec (CG0070), is a targeted oncolytic intravesically delivered immunotherapy agent that is currently in a Phase 3 trial for the treatment of BCG-unresponsive NMIBC. It is also in Phase 2 study in combination with KEYTRUDA® A (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene in combination with OPDIVO® B (nivolumab). We are planning other studies in bladder cancer.


BOND-003 monotherapy

BCG-Unresponsive, High Risk NMIBC


CORE-001 in combination

CG0070 + KEYTRUDA® BCG-Unresponsive, High Risk NMIBC


CORE-002 in combination

CG0070 + OPDIVO® Neoadjuvant in MIBC


Well Positioned to Tackle Different Stages of Bladder Cancer

Other studies are planned in the near future

A KEYTRUDA is a registered trademark of Merck Sharp and Dohme.

B OPDIVO is a registered trademark of Bristol-Myers Squibb Company.